Dow Hits 50K, Cerebras Soars on IPO Day, and Cisco Cuts Jobs

The Dow hit 50000, Cerebras made its market debut and immediately flew higher, and Cisco announced it's cutting jobs at scale to fund its AI pivot.

That would have been enough for one session, but Trump and Xi also reached a Hormuz agreement in Beijing, and oil barely flinched. Today's edition covers all of it.

Tensions in Iran are escalating, not cooling down. Airstrikes continue, oil routes are under pressure, and analysts warn the economic fallout could deepen.

Gas prices are already climbing. Inflation could spike again. And portfolios heavy in stocks and bonds may be exposed if this situation worsens.

That's why many Americans are moving a portion of their retirement savings into physical gold — an asset that historically holds value during periods of conflict and uncertainty.

Red State Gold Group's FREE Gold IRA Guide shows how eligible IRA or 401(k) funds can be rolled into physical gold and silver.

Get your free guide today

Or call (888) 711-2433 for more information.

A major shareholder bought more than $100.5 million worth of stock across three straight sessions in a defensive services company trading near its 52-week low, while the CEO of a beaten-down delivery and ride-hailing platform sold another $1.47 million.

You may see a buy and a sale, but Insider readers will see where big money is stepping into weakness and where leadership is still taking cash out.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Chips are running the show again today as Cisco surged after announcing it's cutting roughly 5% of its workforce this quarter to redirect cash into silicon, optics, and AI, joining a growing list of companies trading headcount for compute capacity.

Cerebras Systems made its Nasdaq debut as the year's biggest IPO, priced at $185 per share and jumping sharply on its first day of trading, making it the AI chip space's most anticipated new entrant of 2026.

Trump and Xi agreed in Beijing that the Strait of Hormuz should remain a free waterway, but oil barely reacted, edging only slightly higher as traders had already priced in the diplomatic meeting.

Retail sales growth slowed in April, and Treasury yields remained elevated above 4.4%, two signals that the impact of the Iran war on inflation is still working through the economy in ways the Dow's new milestone doesn't fully reflect.

BlackRock (NYSE: BLK) just made a major global move by teaming up with Temasek, ADNOC, and Abu Dhabi-backed investors to target up to $30 billion in infrastructure investments across the Gulf and Central Asia.

The scale and partners involved make this stand out. It brings together some of the most powerful capital allocators globally, positioning BlackRock at the center of long-term infrastructure development in a region gaining increasing importance.

From Capital to Control

BlackRock is moving beyond traditional investing. Infrastructure deals like this give influence over physical assets that economies rely on every day.

What stands out to you is how this shifts the company closer to real-world systems rather than just financial markets. That positioning matters. Infrastructure creates long-term control and stable influence across regions.

A Strategic Bet on the Future

The focus on energy, logistics, and transport is not random. These sectors sit at the core of economic growth, especially in regions reshaping global trade and energy flows.

This is where the move becomes bigger. From your angle, this is BlackRock aligning itself with long-term global demand rather than short-term financial cycles.

A Bigger Direction Is Locking In

BlackRock has been expanding into alternative assets for years. This partnership shows how serious that strategy has become, moving into large-scale, globally coordinated investments.

The direction is locking in. What this leaves you with is a company building influence over the infrastructure that powers economies, not just the capital that flows through them.

Mira Pharmaceuticals (NASDAQ: MIRA) just crossed an important line as its lead drug candidate, Ketamir-2, cleared early-stage testing without major safety concerns. The company is now preparing to move into the next phase of clinical trials, where the focus shifts from safety to real-world effectiveness.

This is not just progress; it is the moment where a concept starts turning into a potential product. The milestone matters because early-stage success is what determines whether a drug gets a real shot at becoming commercially viable.

From Idea to Real Development

Phase 1 trials are about proving a drug can safely move forward. Mira has now cleared that barrier, opening the door to testing in actual patients with real conditions.

What stands out to you is how quickly the story shifts from theory to application once this stage is complete. That transition is critical. It moves the company into a much more serious phase of development.

A Bigger Direction Is Taking Shape

Biotech companies are built around moments like this. Each phase unlocks the next level of credibility, funding, and potential partnerships. The direction is locking in.

What this leaves you with is a company moving from early promise into real development territory, where outcomes start to define its future.

The U.S. government pumped more than $1 billion into Intel. The stock popped 128%.

It pumped $400 million into MP Materials.

The stock popped 200%. It bought 10% of Trilogy Metals. The stock popped 500%.

And now, Trump has chosen this AI stock for a $1 billion payday.

Get the free AI stock pick

*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

The Coca-Cola Company (NYSE: KO) just made a major move that goes far beyond launching a new product. The company is rolling out a next-generation global dispensing platform that connects machines, tracks consumer preferences in real time, and turns those insights into new drinks at speed.

The scale is massive. Millions of drinks served daily are now feeding back into a system that directly shapes what gets created next.

From Selling Drinks to Reading Taste

Coca-Cola is no longer just a beverage distributor. It is turning every machine into a live feedback loop, capturing what people choose and how often they come back for it. What stands out to you is how this gives the company a direct line into consumer behavior.

Owning the Moment of Choice

The company is also redesigning how drinks are discovered and served. New machines highlight limited-time options, adapt to different locations, and create a more engaging experience right where the purchase happens.

Coca-Cola is not just competing on brand anymore; it is competing on experience and immediacy.

A Bigger Direction Is Locking In

Coca-Cola is building a system in which product creation, distribution, and customer interaction all connect in a single loop. That kind of integration creates a lasting advantage on a global scale.

The direction is locking in. What this leaves you with is a company turning its entire footprint into a living system, where every interaction shapes what comes next.

Leslie's [LESL] $3.50 (+144.76%)

Leslie's reported Q2 revenue up 4.3% to $184.7 million with comp sales up 6.6%, customer count up 8%, and gross margin improving to 28.9%. Full-year guidance reaffirmed.

The stock was sitting near $1.43 pre-earnings. Still losing money, but the turnaround is no longer theoretical, and today's move proves the market noticed.

Fennec Pharmaceuticals [FENC] $9.24 (+36.48%)

Fennec reported Q1 revenue up 73% to $15.1 million, flipping to its first profitable quarter. Cash grew to $40.1 million, and four PEDMARK abstracts are headed to ASCO.

The $322 million Strong Buy company is expanding into adult cancer populations beyond its pediatric core… the story is getting bigger.

Ondas [ONDS] $11.21 (+26.52%)

Ondas reported Q1 revenue of $50.1 million, a tenfold year-over-year increase beating estimates by 31%, with EBITDA profitability arriving ahead of schedule. Full-year guidance raised to $390 million. BlackRock now holds over 9.3 million shares.

The $5.63 billion Strong Buy autonomous drone platform is scaling, though dilution remains a real risk to watch.

REGENXBIO [RGNX] $6.24 (-37.80%)

REGENXBIO missed Q1 revenue badly ($6.4M vs $26.9M estimate) with a $90.1M net loss and cash running into early 2027. The RGX-202 DMD gene therapy actually hit its Phase III primary endpoint.

Good science, rough finances. The market prioritized the balance sheet, and the stock is now priced accordingly.

Doximity [DOCS] $18.01 (-23.00%)

Doximity beat Q4 revenue, but EPS of $0.26 missed the $0.28 consensus, EBITDA fell 6%, and FY2027 guidance of $664-676 million came in roughly $50 million below what analysts expected.

The stock is now down 57% from its November highs. Four straight beats and still falling — the market doesn't trust the forward picture.

Methode Electronics [MEI] $11.02 (-20.55%)

Methode Electronics is reversing Wednesday's unexplained 47% surge with no confirmed earnings, acquisition, or contract announcement driving the original run.

The stock sat at $9.36 Tuesday before the mystery pop. What goes up without a reason tends to come back down on schedule.

New discussions around financial policy are raising questions about the future of the dollar and asset pricing.

Historically, major shifts have created both risks and opportunities for investors.

Gold, in particular, is once again in focus as a potential beneficiary.

The key is knowing what to watch before any action is taken.

Discover what investors are watching now

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.